Related Experiment Video
Updated: Jun 27, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Amiodarone-induced hypothyroidism with EPO-resistant anemia in a patient with chronic renal failure
1Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
Abstract:
The overall incidence of amiodarone-induced thyroid dysfunction ranges from 2% to 24%. One third to half of patients with hypothyroidism have anemia due to some decrease in normal red blood cell mass and erythropoietin (EPO) resistance. Therefore, for patients with chronic renal disease under medication with amiodarone, early regular thyroid function test should be checked in order to avoid amiodarone-induced hypothyroidism and EPO-resistant anemia. If amiodarone-induced hypothyroidism and EPO-resistant anemia occur in patients with chronic renal failure, early thyroxine should be given instead of waiting for spontaneous recovery by amiodarone discontinuation only. Here, we report a patient with chronic renal failure who developed EPO-resistant anemia after amiodarone treatment for arrhythmia. The hemoglobin level responded to EPO therapy rapidly after thyroxine administration and amiodarone discontinuation.
Related Concept Videos
Hyperthyroidism II: Pathophysiology
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Hypothyroidism II: Pathophysiology
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Hyperthyroidism I: Introduction
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...